The global single nucleotide polymorphism (SNP) genotyping market size was valued at USD 7.24 billion in 2025 and is predicted to hit around USD 19.48 billion by 2034, rising at a 11.7% CAGR, a study ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Therapies for relapsing–remitting multiple sclerosis (RRMS) are only partially effective, and, in most patients receiving such treatment, clinical activity persists. Accurately assessing the treatment ...